"There isn’t full
transparency in what MA costs. There's no publicly available information on a
beneficiary level about the costs of the MA program compared to FFS Medicare.
And it is very, very difficult to figure out the exact risk profile of one
group vs. the other to make that comparison."
— David Mike, a principal and consulting actuary with Milliman,
spoke with AIS's RADAR on Medicare Advantage about MedPAC's recommendation to
"rebalance" the Medicare Advantage benchmark policy.
Subscribers may read the RADAR on Medicare Advantage article in which this quote appeared online. Learn more about subscribing to AIS Health's publications.
No comments:
Post a Comment